Nurix Therapeutics, Inc. (NRIX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-213.0%

-$29.05

vs $25.70 price

Levered DCF

-$38.07

After debt service

Piotroski score

7 / 9

Strong

Altman Z-score

9.1

Safe zone

Rating

A-

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-5.54×	-7.68×	-2.35×	-3.34×	-10.56×	-15.44×	-33.95×	-32.22×
P/B	2.72×	2.82×	1.69×	1.98×	3.61×	2.3×	-12.79×	-8.31×
P/S	17.45×	27.21×	4.39×	15.59×	41.55×	37.49×	23.73×	8.18×
EV / EBITDA	-5.2×	-7.93×	-2.41×	-3.24×	-10.53×	-8.74×	-35.39×	-41.56×
Gross margin	77.5%	-306.3%	-145.7%	-377.6%	-291.4%	-273.1%	-44.7%	-8.2%
Operating margin	-340.2%	-390.5%	-201.4%	-476.0%	-396.3%	-364.7%	-71.5%	-26.0%
Net margin	-314.9%	-354.9%	-187.0%	-466.9%	-393.9%	-242.7%	-69.7%	-25.2%
Current ratio	7.02×	6.46×	3.4×	4.51×	4.7×	6.7×	2.44×	1.24×
Debt / equity	0.1×	0.05×	0.15×	0.04×	0.04×	0×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-49.1%	-36.7%	-71.8%	-59.4%	-34.2%	-14.9%	37.6%	25.6%
Return on invested capital	-47.3%	-36.6%	-56.2%	-52.3%	-28.5%	-12.5%	-79.7%	-77.5%
Return on assets	-38.4%	-28.9%	-40.5%	-43.3%	-24.6%	-10.9%	-49.3%	-20.8%
Free cash flow yield	-18.0%	-12.3%	-26.6%	-28.6%	-7.3%	-0.7%	-0.1%	-10.9%
Earnings yield	-18.0%	-13.0%	-42.6%	-29.9%	-9.5%	-6.5%	-2.9%	-3.1%
Enterprise value	$1.3B	$1.4B	$314M	$549.7M	$1.2B	$548.6M	$703.6M	$280.6M
Net debt / EBITDA	0.78×	0.46×	0.18×	0.31×	0.61×	1.9×	1.75×	3.79×
Cash conversion cycle (days)	-217	-9	-9	-2	55	214	-13	-12